Gumarontinib: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== Gumarontinib == | |||
[[File:Gumarontinib.svg|Chemical structure of Gumarontinib|thumb|right]] | |||
'''Gumarontinib''' is a small molecule [[tyrosine kinase inhibitor]] (TKI) that is primarily used in the treatment of certain types of [[non-small cell lung cancer]] (NSCLC). It is specifically designed to target mutations in the [[epidermal growth factor receptor]] (EGFR), which are commonly found in NSCLC patients. | |||
Gumarontinib | |||
== | == Mechanism of Action == | ||
Gumarontinib | Gumarontinib functions by inhibiting the activity of the EGFR tyrosine kinase. EGFR is a transmembrane protein that, when activated by binding to its specific ligands, triggers a cascade of downstream signaling pathways that promote cell proliferation and survival. In many cancers, including NSCLC, mutations in the EGFR gene lead to its constitutive activation, driving uncontrolled cell division and tumor growth. Gumarontinib binds to the ATP-binding site of the mutated EGFR, thereby blocking its kinase activity and inhibiting tumor cell proliferation. | ||
== | == Clinical Use == | ||
Gumarontinib is | Gumarontinib is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with specific EGFR mutations. These mutations are typically identified through genetic testing of tumor samples. The drug is administered orally and is part of a class of targeted therapies that have improved outcomes for patients with EGFR-mutant NSCLC compared to traditional chemotherapy. | ||
== | == Development and Approval == | ||
Gumarontinib was developed following the discovery of resistance mechanisms to earlier generations of EGFR inhibitors. It is designed to overcome resistance conferred by the T790M mutation, a common secondary mutation that arises in patients treated with first-generation EGFR inhibitors. The development of Gumarontinib involved extensive preclinical studies and clinical trials to establish its efficacy and safety profile. | |||
== | == Side Effects == | ||
Gumarontinib | Common side effects of Gumarontinib include diarrhea, rash, nausea, and fatigue. More serious adverse effects can include interstitial lung disease, liver toxicity, and cardiac effects. Patients receiving Gumarontinib require regular monitoring to manage these potential side effects effectively. | ||
==Related Pages== | == Related Pages == | ||
* [[Epidermal growth factor receptor]] | * [[Epidermal growth factor receptor]] | ||
* [[Non-small cell lung cancer]] | |||
* [[Tyrosine kinase inhibitor]] | * [[Tyrosine kinase inhibitor]] | ||
* [[Cancer treatment]] | * [[Cancer treatment]] | ||
Latest revision as of 01:28, 6 March 2025
Gumarontinib[edit]
Gumarontinib is a small molecule tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically designed to target mutations in the epidermal growth factor receptor (EGFR), which are commonly found in NSCLC patients.
Mechanism of Action[edit]
Gumarontinib functions by inhibiting the activity of the EGFR tyrosine kinase. EGFR is a transmembrane protein that, when activated by binding to its specific ligands, triggers a cascade of downstream signaling pathways that promote cell proliferation and survival. In many cancers, including NSCLC, mutations in the EGFR gene lead to its constitutive activation, driving uncontrolled cell division and tumor growth. Gumarontinib binds to the ATP-binding site of the mutated EGFR, thereby blocking its kinase activity and inhibiting tumor cell proliferation.
Clinical Use[edit]
Gumarontinib is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with specific EGFR mutations. These mutations are typically identified through genetic testing of tumor samples. The drug is administered orally and is part of a class of targeted therapies that have improved outcomes for patients with EGFR-mutant NSCLC compared to traditional chemotherapy.
Development and Approval[edit]
Gumarontinib was developed following the discovery of resistance mechanisms to earlier generations of EGFR inhibitors. It is designed to overcome resistance conferred by the T790M mutation, a common secondary mutation that arises in patients treated with first-generation EGFR inhibitors. The development of Gumarontinib involved extensive preclinical studies and clinical trials to establish its efficacy and safety profile.
Side Effects[edit]
Common side effects of Gumarontinib include diarrhea, rash, nausea, and fatigue. More serious adverse effects can include interstitial lung disease, liver toxicity, and cardiac effects. Patients receiving Gumarontinib require regular monitoring to manage these potential side effects effectively.
